"IMU has been remiss in HerVaxx reporting. The trial started in Aug-2017 and was to have recruited 68 patients. After over three years, it only recruited 27. We got no indication that the trial was so far behind schedule."
- Aug-2017 was for Phase 1b. Our Phase 2 only started in early-2019. All progress including first patient recruited and clinical update were announced by the company. - Spend some time and look through the list of announcements: https://www.imugene.com/announcements ...and you'll soon find out how wrong you are.
"By the company's own admission, its most advanced trial (Her-Vaxx) will take until end 2021 just to get to the 34 patients that the IDMC has recommended. This still won't be enough to pass regulatory hurdles."
- What you think will or won't pass regulatory authority is immaterial and irrelevant, when we have some of the leading figures in the industry on our SAB and management team.
"There is no reporting on the efficacy of any of its other drugs in sight. There is no drug approval in sight. There is no revenue in sight. Given its R&D program, the company cannot get to revenue even with its current cash reserves."
- This is why Imugene is categorised as an early stage biotech company. If its pipeline were any more advanced, would you seriously think the share price would be at $0.10-$0.14?
"The SP will jump significantly if a big pharma deal comes along. Will it come? When will it come? are question no one on this site can answer."
- That is why it's called speculative. If anyone did have the answer then that would either be insider trading, a time traveller or a clairvoyant.
By the sounds of it, I believe CSL and NAN are more up your alley.
IMU Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
(20min delay)
